Latest Issue
Get instant access to latest e-book

LATEST NEWSRead more...

24

Jan 2020

Evotec and Indivumed Announce Second Joint Drug Discovery Program

Evotec SE and Indivumed GmbH announced that the companies have entered into a new research collaboration to discover and develop firstinclass therapeutics for the treatment of nonsmall cell lung cancer NSCLC The final goal of this precision medicine collaboration is to deliver highly effective treat...

24

Jan 2020

Sanofi Completes Acquisition of Synthorx, Inc.

Sanofi announced the successful completion of its acquisition of Synthorx Inc for per share in cash The acquisition of Synthorx perfectly aligns with our RD strategy enhancing our position as an emerging leader in the area of oncology and immunology

23

Jan 2020

INHIBITOR Therapeutics Receives prostate cancer IND Clearance from FDA

INHIBITOR Therapeutics Inc a biopharmaceutical company focused on the discovery development and commercialization of innovative therapeutics to inhibit progression of cancerous and noncancerous proliferation disorders today announced that the company has received Investigational New Drug IND clearan...

23

Jan 2020

Genialis and Oncologie Collaborate on Precision Medicine Initiative in Gastric Cancer

Genialis a leader in applied data science for the development of precision medicines today announced a collaborative partnership with Oncologie an international clinicalstage biopharma developing nextgeneration immunotherapies for cancer Initial activities will focus on the use of Genialis Expressio...

22

Jan 2020

Hitachi Chemical Advanced Therapeutics Solutions and Ori Biotech Announce a Joint Development Agreement

Hitachi Chemical Advanced Therapeutics Solutions LLC HCATS a US subsidiary of Hitachi Chemical Co Ltd that engages in contract manufacturing and manufacturing development of cell therapy products and Ori Biotech Ltd Ori an innovator in cell and gene therapy CGT manufacturing today announced they hav...

22

Jan 2020

Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies

Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell iPSCderived cardiomyocytes Under the terms of the agreement Bluerock gains access to Ncardias largescale production processes and intellectual...

21

Jan 2020

Crescita Signs Exclusive Distribution Agreement with FILLMED

Crescita Therapeutics Inc a commercial dermatology company with manufacturing capabilities and a portfolio of nonprescription skincare products and prescription drug products for the treatment and care of skin conditions diseases and their symptoms today announced that it has entered into a distribu...

press releasesRead more...

24

Jan 2020

European CNS Specialist Neuraxpharm Strengthens Expansion into Austrian Market with Acquisition of easypharm

Neuraxpharm Group Neuraxpharm a leading European specialty pharmaceutical company focused on central nervous system CNS disorders today announces the expansion of its operations in Central Europe with the launch of Neuraxpharm Austria and the acquisition of Easypharm OTC GmbH a privatelyowned Austri...

24

Jan 2020

Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti™

Evoke Pharma Inc a specialty pharmaceutical company focused on treatments for gastrointestinal GI diseases and EVERSANA an independent provider of global commercial services to the life science industry today announced a collaboration to utilize EVERSANAs integrated suite of outsourced services to c...

23

Jan 2020

Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy

Jazz Pharmaceuticals plc announced the submission of a New Drug Application NDA to the US Food and Drug Administration on January seeking marketing approval for JZP an investigational medicine for the treatment of cataplexy and excessive daytime sleepiness EDS in patients years of age and older...

23

Jan 2020

Aruvant Receives Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease

Aruvant a clinicalstage biopharmaceutical company focused on developing and commercializing transformative therapies for the treatment of severe blood disorders today announced that the US Food and Drug Administration has granted Orphan Drug designation to ARU Aruvants investigational therapy for th...

22

Jan 2020

Denovo Biopharma Enters into Option Agreement with Rumpus Therapeutics for Selected DB102 (Enzastaurin) Clinical Indications

Denovo Biopharma LLC a pioneer in applying precision medicine to develop innovative therapies today announced it has entered into an exclusive OptiontoLicense Agreement with Rumpus Therapeutics for selected indications for DB Rumpus Therapeutics gains the option to acquire an exclusive license to de...

22

Jan 2020

OBI Pharma Granted U.S. FDA Orphan Drug Designation for the Treatment of Gastric Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999

OBI Pharma Inc a Taiwan biopharma company TPEx today announced that the US Food and Drug Administration FDA has granted Orphan Drug Designation for OBI for the treatment of Gastric Cancer OBI is a firstinclass antibody drug conjugate targeting Globo H a glycolipid antigen On December OBI was gran...

EventsRead more...

24 - 25

Jan 2020

27 - 30

Jan 2020

Arab Health 2020

Dubai World Trade Centre

28 - 30

Jan 2020

2nd Longevity Therapeutics 2020

Holiday Inn Golden Gateway Hotel

28 - 30

Jan 2020

29 - 30

Jan 2020

03 - 06

Feb 2020

Medlab Middle East 2020

Dubai World Trade Centre

04 - 05

Feb 2020

14th annual Parallel Trade conference

Holiday Inn London - Kensington Forum

05 - 07

Feb 2020

The Biologics Alliance 2020

ICRS - International Cartilage Regeneration & Joint Preservation Society
Carlsbad

Advertisements

TOP ARTICLES

KNOWLEDGE BANK

  • Interviews

    Merck

    Staff Engineer, Manufacturing Science and Technology, South East Asia

    Karen Chan is a process engineer at Merck Pte Ltd Chan has six years of experience in the biopharmaceutical industry and two years of experience in research development She provides technical support in areas such as process development troubleshoot...
  • Articles

    Treatment of Cancer Using Combined Chemo-Photo Approach

    Cancer is one of the leading causes of death in both developed and developing countries and also a major public health problem This dreadful disease is spreading with continuance and increasing incidences in recent times In million cancer patients died as per the reports of World Health Organization WHO which also estimated the increase in annual cancer cases

EDITORIAL SECTION

  • EXPERT Talk

    PHARMA LOGISTICS TRENDS

    Pharma logistics is undergoing profound change throughout Asia as the ageing population drives a growing need for new pharma solutions together with s...